5 min read
Trial Tuesday: New Keys, Old Questions
Ionis was getting ready to cut the cake and blow out the candles on its first independent neurology launch. Then Ultragenyx's Phase III failure in Angelman syndrome arrived and put a damper on the celebrations. The party is still on, but the mood has definitely shifted.
